VERA THERAPEUTICS INC
Vera Therapeutics Inc (VERA) is a clinical-stage biotechnology company developing novel therapies targeting immune-mediated and respiratory conditions. With a market capitalisation of around US$1.94bn, it attracts attention from investors interested in innovation-driven small caps. The company’s value largely depends on pipeline progress, clinical trial results and regulatory milestones, so share price can be volatile. For long-term investors, key considerations include the strength of the balance sheet, upcoming data readouts, partner and licensing agreements, and competitive landscape. Vera may offer upside if trials succeed, but there is significant risk if development programmes encounter delays or negative results. This summary provides general, educational information — not personalised investment advice. Investors should review company filings, seek professional advice if needed and only invest money they can afford to risk, because biotech stocks can experience wide price swings and outcomes are uncertain.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying VERA's stock, expecting it to reach a higher price of $68.77.
Financial Health
VERA Therapeutics is showing strong cash generation and a solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring VERA
The Post-Pandemic Pediatric Pivot
The FDA's potential withdrawal of Pfizer's COVID vaccine for young children is reshaping the pediatric pharmaceutical landscape. This regulatory shift could create a significant market opening for other drugmakers focused on pediatric vaccines and therapies.
Published: August 13, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage focus
Pipeline milestones and trial readouts are primary value drivers; successful data can boost prospects, though outcomes are uncertain and can move prices sharply.
Scientific innovation
Investment interest often centres on novel approaches and partnerships, but scientific promise does not guarantee commercial success.
Market dynamics
Competition, regulatory environment and financing needs shape the opportunity; consider diversification since biotech stocks can be volatile.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
